Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Revenues Down, Losses Up in Q1

NEW YORK, April 26-CuraGen said yesterday that revenues had  slipped and net loss had nearly quadrupled for the first quarter of 2002.


For the quarter ended March 31, 2002, the company reported revenues of $4.8 million, down 16 percent from the equivalent quarter last year.


R&D was up 66 percent to $20.1 million as compared to the same reporting period in 2001.


CuraGen's net loss for the quarter was $19.6 million or 40 cents per common share. For Q1 in 2001, its loss was $5.4 million or 11 cents per share.


The company also reported cash resources and short-term investments of about $478 million.


CuraGen hopes to file its first IND with the Food & Drug Administration within six to 12 months.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.